Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) had its target price upped by investment analysts at Robert W. Baird from $132.00 to $160.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Robert W. Baird's price objective suggests a potential upside of 28.61% from the stock's previous close.
Other research analysts have also issued reports about the company. Wells Fargo & Company upped their price objective on Axsome Therapeutics from $140.00 to $160.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Truist Financial raised their price target on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. StockNews.com upgraded shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Leerink Partners lifted their price objective on Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a report on Monday, February 10th. Finally, Royal Bank of Canada increased their price target on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $167.36.
View Our Latest Stock Report on AXSM
Axsome Therapeutics Stock Performance
Shares of Axsome Therapeutics stock traded down $0.69 during trading on Monday, hitting $124.41. 553,470 shares of the stock were exchanged, compared to its average volume of 1,040,183. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $139.13. The stock has a market capitalization of $6.07 billion, a price-to-earnings ratio of -20.77 and a beta of 0.99. The company has a fifty day moving average price of $107.34 and a 200-day moving average price of $97.28. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. As a group, equities analysts predict that Axsome Therapeutics will post -2.79 EPS for the current fiscal year.
Insider Buying and Selling at Axsome Therapeutics
In other news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 22.40% of the company's stock.
Institutional Investors Weigh In On Axsome Therapeutics
Institutional investors have recently made changes to their positions in the business. Raiffeisen Bank International AG bought a new position in Axsome Therapeutics during the 4th quarter valued at approximately $51,000. Assetmark Inc. purchased a new position in Axsome Therapeutics in the fourth quarter worth about $52,000. R Squared Ltd purchased a new stake in Axsome Therapeutics during the 4th quarter valued at $64,000. Aquatic Capital Management LLC purchased a new position in Axsome Therapeutics in the 4th quarter worth about $76,000. Finally, GF Fund Management CO. LTD. bought a new position in Axsome Therapeutics during the fourth quarter valued at approximately $86,000. Hedge funds and other institutional investors own 81.49% of the company's stock.
About Axsome Therapeutics
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Read More
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
